Meltem İNAL, Özge KURUMUŞ, Sedef Gülçin URAL, Hatice TOLUNAY

Anticoagulant And Antiplatelet Medication Awareness Of Preoperative Patients

Objective: To determine anticoagulant and anti-platelet medication awareness of peri-operative patientsMethod: A questionnaire was applied to the 208 preoperative patients taking anticoagulants (AC) or anti-platelets (AP). The questionnaire included the questions about whether they were using any drug that thinners blood or prevents clots, indication and duration of drug use, whether they underwent an operation while using the drug, whether they knew that the drug should be discontinued in case of undergoing an operation and presence of a planned surgical procedure when commencing the drug.Results: Mean age of the study population was 63.3±12.7 years and 50.5% of the patients were male, 27.9 % of the patients were illiterate, 39.4% of patients were not aware of using AC or AP and 12.5% of patients didn’t know duration of AC or AP use. An operation had been planned before commencement of the drug in 9.1% of the patients. The incidence of undergoing a surgical procedure while using AC or AP was 18.8%. While 23.1 % were urgent, 76.9% were elective procedures. General anesthesia was applied in 41% of these patients. When the patients who were aware or unaware of AC or AP use were compared, mean age was younger and level of education was higher among the patients who were aware of using AC or AP (p=0,018 and p

Ameliyat Öncesi Değerlendirilen Hastaların Antikoagülan ve Antiplatelet İlaç Kullanım Farkındalığı

Amaç: Ameliyat planlanan hastaların kullanmakta oldukları antikoagulan ilaçlar (AKİ) ve antiplatelet ilaçlar (APİ) hakkındaki farkındalıklarını belirlemek çalışmanın amacıdır. Yöntemler: AKİ veya APİ kullanan 208 hastaya preoperatif değerlendirmede anket uygulandı. Hastalara AKİ veya APİ kullanıp kullanmadığı, ilacın niçin başladığı, ne kadar süredir almakta olduğu, ilaç kullanımı sırasında cerrahi müdahale geçirip geçirmediği, geçirmesi gerekli durumda ilacın kesilmesini bilip bilmediği, ilaç başlanırken planlı bir operasyon hikayesi varlığı soruldu. Bulgular: Ortalama yaş 63,3±12,7 idi. Hastaların %50,5'i erkekti, %27,9'u okuryazar değildi, %39,4'ü AKİ veya APİ kullandığını bilmiyordu, %12,5 'i ne kadar süredir kullandığını bilmiyordu. Hastaların %9,1'inin ilaca başlanmadan önce planlanmış operasyonu mevcuttu. İlaç kullanırken operasyon geçirme oranı %18,8 idi, bunların %23,1'ini acil, %76,9'unu elektif operasyonlar oluşturuyordu. %41,0'na genel anestezi altında işlem uygulanmıştı. AKİ veya APİ kullandığının farkında olanlar ile farkında olmayanlar karşılaştırıldığında, farkında olanların yaş ortalamasının küçük ve okur yazarlık oranın fazla olduğu görüldü (p=0,018, p

PDF

___

1.Murray CJ, Lopez AD. Alternative projections ofmortality and disability by cause 1990-2020: GlobalBurden of Disease Study. Lancet. 1997; 349: 1498-504.

2.Korte W, Cattaneo M, Chassot PG, et al. Peri-operative management of antiplatelet therapy inpatients with coronary artery disease. ThrombHaemost. 2011; 105: 743-9.

3.Kristensen SD, Knuuti J, Saraste A, et al. 2014ESC/ESA Guidelines on non-cardiac surgery:cardiovascular assessment and management: TheJoint Task Force on non-cardiac surgery:cardiovascular assessment and management of theEuropean Society of Cardiology (ESC) and theEuropean Society of Anaesthesiology (ESA). EurHeart J. 2014; 35: 2383-431.

4.Wiviott SD, Braunwald E, Mc Cabe CH, et al.Prasugrel versus clopidogrel in patients with acutecoronary syndromes. N Engl J Med. 2007; 357: 2001-15.

5.Wallentin L, BeckerRC, Budaj A, et al. Ticagrelorversus clopidogrel in patients with acute coronarysyndromes. N Engl J Med 2009; 361: 1045-57.

6.Head DE, Sebranek JJ, Zahed C, Coursin DB,Prielipp RC. A tale of two stents:perioperativemanagement of patients with drug-eluting coronarystents. J Clin Anesth. 2007; 19: 386-96.

7.Windecker S, Kolh P, Alfonso F, et al. 2014ESC/EACTS Guidelines on myocardialrevascularization: The Task Force on MyocardialRevascularization of the European Society ofCardiology (ESC) and the European Association forCardio Thoracic Surgery (EACTS) Developed withthe special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35: 2541-619.

8.King SB, Smith SC Jr, Hirshfeld JW Jr, et al. 2007Focused Update of the ACC/AHA/SCAI 2005Guideline Update for Percutaneous CoronaryIntervention. Circulation. 2008; 117: 261-95.

9.Iakovou I, Schmidt T, Bonizzoni E, et al. Incidencepredictors, and outcome of thrombosis aftersuccessful implantation of drug-eluting stents.JAMA. 2005; 293: 2126-30.

10.Schouten O, van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: earlysurgery and interruption of antiplatelet therapy areassociated with an increase in major adverse cardiac events. J Am Coll Cardio. 2007; 49: 122-4.

11.Parolari A, Mussoni L, Frigerio M, et al. Increasedprothrombotic state lasting as long as one monthafter on-pump and off-pump coronary surgery. JThorac Cardiovasc Surg. 2005; 130: 303-8.

12.Lison S, Weiss G, Spannagl M, Heindl B.Postoperative changes in procoagulant factors aftermajor surgery. Blood Coagul Fibrinolysis. 2011; 22:190-6.

13.Savonitto S, Caracciolo M, Cattaneo M, DE Servi S. Management of patients with recently implantedcoronary stents on dual antiplatelet therapy whoneed to undergo major surgery. J Thromb Haemost.2011; 9: 2133-42.

14.Vicenzi MN, Meislitzer T, Heitzinger B, et al.Coronary artery stenting and non-cardiac surgery-aprospective outcome study. Br J Anaesth. 2006; 96:686-93.

15.Berger PB, Kleiman NS, Pencina MJ, et al.Frequency of major noncardiac surgery andsubsequent adverse events in the year after drug-eluting stent placement results from the EVENT(Evaluation of Drug-Eluting Stents and IschemicEvents) Registry. JACC Cardiovasc Interv. 2010; 3:920-7.

16.To AC, Armstrong G, Zeng I, Webster MW.Noncardiac surgery and bleeding afterpercutaneous coronary intervention. CircCardiovasc Interv. 2009; 2: 213-21.

17.Brilakis ES, Banerjee S, Berger PB. Perioperativemanagement of patients with coronary stents. J AmColl Cardiol. 2007; 49: 2145-50.

18.Acar A, Hasbahçeci M, Başak F, et al. Bleedingscaused by warfarin overdose. Dicle Med J. 2012; 39:223-6.

19.Favaloro EJ, Lippi G. The new oral anticoagulantsand the future of haemostasis laboratory testing.Biochem Med. 2012; 22: 329-41.

20.Pinho-Gomes AC, Hague A, Ghosh J. Managementof novel oral anticoagulants in emergency andtrauma surgery. Surgeon. 2016; 14: 234-9.